These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 18381791

  • 1. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
    Abdou NI, Rider V, Greenwell C, Li X, Kimler BF.
    J Rheumatol; 2008 May; 35(5):797. PubMed ID: 18381791
    [Abstract] [Full Text] [Related]

  • 2. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus.
    Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI.
    J Rheumatol; 2001 Dec; 28(12):2644-9. PubMed ID: 11764210
    [Abstract] [Full Text] [Related]

  • 3. Differential expression of estrogen receptors in women with systemic lupus erythematosus.
    Rider V, Li X, Peterson G, Dawson J, Kimler BF, Abdou NI.
    J Rheumatol; 2006 Jun; 33(6):1093-101. PubMed ID: 16755656
    [Abstract] [Full Text] [Related]

  • 4. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
    Mok CC, Ying SK, Ma KM, Wong CK.
    Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
    [Abstract] [Full Text] [Related]

  • 5. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
    Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group.
    Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells.
    Rider V, Jones SR, Evans M, Abdou NI.
    Clin Immunol; 2000 May; 95(2):124-34. PubMed ID: 10779406
    [Abstract] [Full Text] [Related]

  • 7. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR, Sato EI.
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [Abstract] [Full Text] [Related]

  • 8. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS, Pereira FV, de Sá MF, Paulo LJ, Martins WP, Ferriani RA.
    Maturitas; 2009 Mar 20; 62(3):311-6. PubMed ID: 19193505
    [Abstract] [Full Text] [Related]

  • 9. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E.
    Osteoporos Int; 2004 May 20; 15(5):396-404. PubMed ID: 14676992
    [Abstract] [Full Text] [Related]

  • 10. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN, Liu CS, Tsai TR, Hung YC, Chang SJ, Lin HL, Chen YC, Lai HM, Yu SF, Chen CJ.
    Kaohsiung J Med Sci; 2011 Jul 20; 27(7):251-7. PubMed ID: 21757141
    [Abstract] [Full Text] [Related]

  • 11. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.
    Arthritis Rheum; 2004 Sep 20; 50(9):2858-68. PubMed ID: 15452837
    [Abstract] [Full Text] [Related]

  • 12. Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms.
    Rider V, Keltner S, Abdou NI.
    J Gend Specif Med; 2003 Sep 20; 6(2):14-21. PubMed ID: 12813997
    [Abstract] [Full Text] [Related]

  • 13. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study.
    Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW.
    J Rheumatol; 2000 Jul 20; 27(7):1759-65. PubMed ID: 10914864
    [Abstract] [Full Text] [Related]

  • 14. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, Weisman MH.
    Rheumatology (Oxford); 2008 Mar 20; 47(3):334-8. PubMed ID: 18238794
    [Abstract] [Full Text] [Related]

  • 15. Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus.
    Urquizu-Padilla M, Balada E, Cortés F, Pérez EH, Vilardell-Tarrés M, Ordi-Ros J.
    J Rheumatol; 2009 May 20; 36(5):953-60. PubMed ID: 19332622
    [Abstract] [Full Text] [Related]

  • 16. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C.
    Cancer; 2003 Jul 15; 98(2):229-38. PubMed ID: 12872340
    [Abstract] [Full Text] [Related]

  • 17. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov 15; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 18. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial.
    Mok CC, Wong CK, To CH, Lai JP, Lam CS.
    Arthritis Care Res (Hoboken); 2011 Jun 15; 63(6):875-83. PubMed ID: 21309005
    [Abstract] [Full Text] [Related]

  • 19. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W.
    Arthritis Rheum; 2008 Aug 15; 58(8):2453-9. PubMed ID: 18668552
    [Abstract] [Full Text] [Related]

  • 20. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, Yaal-Hahoshen N.
    Isr Med Assoc J; 2008 May 15; 10(5):339-43. PubMed ID: 18605354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.